TIGIT and breast carcinoma: In this study, TIGIT involvement in anti-tumor CD8+ responses was investigated, and TIGIT was shown to be highly expressed on TILs in human lung squamous cell carcinoma, colon adenocarcinoma, uterine corpus endometroid carcinoma, breast cancer, and renal clear cell carcinoma.